TTC13

Across TCGA pan-cancer cohorts, TTC13 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TTC13 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TTC13 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TTC13 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

PDAC, LSCC, and HNSC are the cancer types where TTC13 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.265	0.524	.001	24	view →
LSCC	OS	Quartile	All	0.699	0.955	.015	9	view →
HNSC	DFS	Quartile	All	0.904	0.674	.011	7	view →
CCRCC	OS	Median	All	0.982	0.899	.022	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TTC13–PDAC (DFS)

Open the PDAC breakdown →